[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,797
  • Shares Outstanding, K 22,983
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,470 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.21

Options Overview Details

View History
  • Implied Volatility 235.01% (+52.81%)
  • Historical Volatility 113.85%
  • IV Percentile 46%
  • IV Rank 13.05%
  • IV High 1,197.14% on 12/15/25
  • IV Low 90.64% on 01/15/26
  • Expected Move (DTE 29) 0.0595 (4.44%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 149
  • Volume Avg (30-Day) 192
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 6,093
  • Open Int (30-Day) 5,304
  • Expected Range 1.2805 to 1.3995

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) +768,561.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +12.30%
on 06/12/26
1.9300 -29.02%
on 05/28/26
-0.1400 (-9.27%)
since 05/18/26
3-Month
0.8700 +57.47%
on 03/30/26
1.9300 -29.02%
on 05/28/26
+0.2500 (+22.32%)
since 03/18/26
52-Week
0.8500 +61.18%
on 02/05/26
2.2299 -38.56%
on 11/05/25
+0.0300 (+2.24%)
since 06/18/25

Most Recent Stories

More News
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces...

NNVC : 1.4100 (+5.22%)
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces...

NNVC : 1.4100 (+5.22%)
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential...

NNVC : 1.4100 (+5.22%)
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum...

NNVC : 1.4100 (+5.22%)
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical...

NNVC : 1.4100 (+5.22%)
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum...

NNVC : 1.4100 (+5.22%)
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March 31,...

NNVC : 1.4100 (+5.22%)
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical...

NNVC : 1.4100 (+5.22%)
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2026,...

NNVC : 1.4100 (+5.22%)
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum...

NNVC : 1.4100 (+5.22%)

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.4779
2nd Resistance Point 1.4389
1st Resistance Point 1.3895
Last Price 1.4100
1st Support Level 1.3011
2nd Support Level 1.2621
3rd Support Level 1.2127

See More

52-Week High 2.2299
Fibonacci 61.8% 1.7028
Fibonacci 50% 1.5399
Last Price 1.4100
Fibonacci 38.2% 1.3771
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.